Strategies to re-express epigenetically silenced p15INK4b and p21WAF1 genes in acute myeloid leukemia

Epigenetics

Volumn 5, Issue 8, 2010, Pages 696-703

  Geyer, C Ronald ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

AML; DNA methylation; Epigenetics; Histone acetylation; Histone methylation; Natural antisense transcripts; Non coding RNA

Indexed keywords

3 DEAZANEPLANOCIN A; AZACITIDINE; BIX 01294; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2B; DEOXYCYTIDINE; DNA; HISTONE DEACETYLASE INHIBITOR; POMALIDOMIDE; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; UNCLASSIFIED DRUG; CDKN1A PROTEIN, HUMAN; CDKN2B PROTEIN, HUMAN; COMPLEMENTARY RNA; CYCLIN DEPENDENT KINASE INHIBITOR 1A; UNTRANSLATED RNA;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; ANTISENSE THERAPY; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CHROMATIN CONDENSATION; CLONOGENESIS; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; GENE SILENCING; GENOME IMPRINTING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MONOCYTOSIS; NONHUMAN; TRANSCRIPTION REGULATION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; REVIEW;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; GENE EXPRESSION REGULATION, LEUKEMIC; GENE SILENCING; HUMANS; LEUKEMIA, MYELOID, ACUTE; RNA, ANTISENSE; RNA, UNTRANSLATED;

EID: 78449266144     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.5.8.13276     Document Type: Article

References (89)

1. Piacibello W, Severino A, Stacchini A, Aglietta M. Differential effect of transforming growth factor beta 1 on the proliferation of human lymphoid and myeloid leukemia cells. Haematologica 1991; 76: 17-9.
2. Kim SJ, Letterio J. Transforming growth factor-beta signaling in normal and malignant hematopoiesis. Leukemia 2003; 17:1731-7.
3. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4:143-53.
4. Cameron EE, Bachman KE, Myöhänen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21:103-7.
5. Ren L, Du H, Zhu Q, Shi Y, Chen H, Wu S. The re-expression of p15(INK4B) gene in leukemia cells induced by in vitro DNA methyltransferase and histone deacetylase inhibition. Zhonghua Nei Ke Za Zhi 2002; 41:762-5.
6. Farinha NJ, Shaker S, Lemaire M, Momparler L, Bernstein M, Momparler RL. Activation of expression of p15, p73 and E-cadherin in leukemic cells by different concentrations of 5-aza-2'-deoxycytidine (Decitabine). Anticancer Res 2004; 24:75-8.
7. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Köhler G, Wijermans P, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 2002; 100:2957-64.
8. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyl-transferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006; 66:6361-9.
9. INK4b DNA methylation in AML. Blood 2010; 115:3098-108.
10. WAF1 promoter demethylation. Leuk Res 2006; 30:69-76.
11. Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A. Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 2009; 125:1168-76.
12. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A, et al. Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-dea-zaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 2009; 114:2733-43.
13. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, et al. p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene 2008; 27:3615-23.
14. WAF1 expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer 2005; 114:683-95.
15. Abujamra AL, Dos Santos MP, Roesler R, Schwartsmann G, Brunetto AL. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk Res 2010; 34:687-95.
16. Lakshmikuttyamma A, Scott SA, DeCoteau JF, Geyer CR. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition. Oncogene 2010; 29:576-88.
17. Wenqiang Y, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, et al. Epigenetic silencing of tumour suppressor gene p15: by its antisense RNA. Nature 2008; 451:202-6.
18. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, et al. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 2010; 38:662-74.
19. Morris KV, Santoso S, Turner AM, Pastori C, Hawkins PG. Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet 2008; 4:1000258.
20. Ink4b: dual function in myelopoiesis and inactivation in myeloid disease. Blood Cells Mol Dis 2008; 40:406-9.
21. Krug U, Ganser A, Koeffler HP. Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 2002; 21:3475-95.
22. Raj K, John A, Ho A, Chronis C, Khan S, Samuel J, et al. CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine. Leukemia 2007; 21: 1937-44.
23. Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009; 23:1019-28.
24. INK4b results in monocytosis and predisposition to myeloid leukemia. Blood 2010; [Epub ahead of print].
25. Ogawa M, Sakashita K, Zhao XY, Hayakawa A, Kubota T, Koike K. Analysis of histone modification around the CpG island region of the p15 gene in acute myeloblastic leukemia. Leuk Res 2007; 31:611-21.
26. Kouzarides T. Chromatin modifications and their function. Cell 2007; 128:693-705.
27. WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood 2004; 103:743-6.
28. Brakensiek K, Länger F, Kreipe H, Lehmann U. Absence of p21(CIP 1), p27(KIP 1) and p57(KIP 2) methylation in MDS and AML. Leuk Res 2005; 29:1357-60.
29. Chim CS, Wong ASY, Kwong YL. Epigenetic inactivation of the CIP/KIP cell cycle control pathway in acute leukemias. Am J Hemat 2005; 80:282-7.
30. WAF1 expression and gene-associated histone acetylation. P Natl Acad Sci USA 2000; 97:10014-9.
31. Sowa Y, Orita T, Minamikawa S, Nakano K, Mizuno T, Nomura H, et al. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997; 241:142-50.
32. WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009; 69:7347-56.
33. Cip/WAF1 by recruitment of histone lysine methyltransferase G9a and histone deacetylase 1. Mol Cell Biol 2005; 25:10338-51.
34. Cherrier T, Suzanne S, Redel L, Calao M, Marban C, Samah B, et al. p21(WAF1) gene promoter is epigenetically silenced by CTIP2 and SUV39H1. Oncogene 2009; 28:3380-9.
35. Nishioka C, Ikezoe T, Yang J, Komatsu N, Koeffler HP, Yokoyama A. Blockade of MEK signaling potentiates 5-Aza-2'-deoxycytidine-induced apoptosis and upregulation of p21(waf1) in acute myelogenous leukemia cells. Int J Cancer 2009; 125:1168-76.
36. Tufarelli C. The silence RNA keeps: cis mechanisms of RNA mediated epigenetic silencing in mammals. Philos Trans R Soc Lond B Biol Sci 2006; 361:67-79.
37. Sleutels F, Tjon G, Ludwig T, Barlow DP. Imprinted silencing of Slc22a2 and Slc22a3 does not need transcriptional overlap between Igf2r and Air. EMBO J 2003; 22:3696-704.
38. Thakur N, Tiwari VK, Thomassin H, Pandey RR, Kanduri M, Göndör A, et al. An antisense RNA regulates the bidirectional silencing property of the Kcnq1 imprinting control region. Mol Cell Biol 2004; 24:7855-62.
39. Kawasaki H, Taira K. Induction of DNA methylation and gene silencing by short interfering RNAs in human cells. Nature 2004; 431:211-7.
40. Morris KV, Chan SW, Jacobsen SE, Looney DJ. Small interfering RNA-induced transcriptional gene silencing in human cells. Science 2004; 305:1289-92.
41. Tufarelli C, Stanley JA, Garrick D, Sharpe JA, Ayyub H, Wood WG, et al. Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease. Nat Genet 2003; 34:157-65.
42. Lapidot M, Pilpel Y. Genome-wide natural antisense transcription: coupling its regulation to its different regulatory mechanisms. EMBO Rep 2006; 7: 1216-22.
43. Sleutels F, Tjon G, Ludwig T, Barlow DP. Imprinted silencing of Slc22a2 and Slc22a3 does not need transcriptional overlap between Igf2r and Air. EMBO J 2003; 22:3696-704.
44. Thakur N, Tiwari VK, Thomassin H, Pandey RR, Kanduri M, Göndör A, et al. An antisense RNA regulates the bidirectional silencing property of the Kcnq1 imprinting control region. Mol Cell Biol 2004; 24:7855-62.
45. Umlauf D, Goto Y, Cao R, Cerqueira F, Wagschal A, et al. Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet 2004; 36:1296-300.
46. Lewis A, Mitsuya K, Umlauf D, Smith P, Dean W, Walter J, et al. Imprinting on distal chromosome 7 in the placenta involves repressive histone methylation independent of DNA methylation. Nat Genet 2004; 36:1291-5.
47. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA, et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129:1311-23.
48. Mohammad F, Mondal T, Guseva N, Pandey GK, Kanduri C. Kcnq1ot1 noncoding RNA mediates transcriptional gene silencing by interacting with Dnmt1. Development 2010; 137:2493-9.
49. Nagano T, Mitchell JA, Sanz LA, Pauler FM, Ferguson-Smith AC, Feil R, et al. The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science 2008; 322:1717-20.
50. Cliffe AR, Garber DA, Knipe DM. Transcription of the herpes simplex virus latency associated transcript promotes the formation of facultative heterochromatin on lytic promoters. J Virol 2009; 83:8182-90.
51. Wang QY, Zhou C, Johnson KE, Colgrove RC, Coen DM, Knipe DM. Herpesviral latency-associated transcript gene promotes assembly of heterochromatin on viral lytic-gene promoters in latent infection. P Natl Acad Sci USA 2005; 102:16055-9.
52. Schwartz JC, Younger ST, Nguyen NB, Hardy DB, Monia BP, Corey DR, et al. Antisense transcripts are targets for activating small RNAs. Nat Struct Mol Biol 2008; 15:842-8.
53. Muchardt C, Guilleme M, Seeler JS, Trouche D, Dejean A, Yaniv M. Coordinated methyl and RNA binding is required for heterochromatin localization of mammalian HP1alpha. EMBO Rep 2002; 3: 975-81.
54. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, et al. Small dsRNAs induce transcriptional activation in human cells. P Natl Acad Sci USA 2006; 103:17337-42.
55. Bernstein E, Duncan EM, Masui O, Gil J, Heard E, Allis CD. Mouse polycomb proteins bind differentially to methylated histone H3 and RNA and are enriched in facultative heterochromatin. Mol Cell Biol 2006; 26:2560-9.
56. Jeffery L, Nakielny S. Components of the DNA methylation system of chromatin control are RNA-binding proteins. J Biol Chem 2004; 279:49479-87.
57. Lopez-Serra L, Ballestar E, Ropero S, Setien F, Billard LM, Fraga MF, et al. Unmasking of epigenetically silenced candidate tumor suppressor genes by removal of methyl-CpG-binding domain proteins. Oncogene 2008; 27:3556-66.
58. Lee JT. Lessons from X-chromosome inactivation: long ncRNA asguides and tethers to the epigenome. Genes Dev 2009; 23:1831-42.
59. Ponting CP, Oliver PL, Reik W. Evolution and functions of long noncoding RNAs. Cell 2009; 136: 629-41.
60. Umlauf D, Fraser P, Nagano T. The role of long non-coding RNAs in chromatin structure and gene regulation: variations on a theme. Biol Chem 2008; 389:323-31.
61. Zaratiegui M, Irvine D, Martienssen R. Noncoding RNAs and gene silencing. Cell 2007; 128:763-76.
62. Morris KV. Long antisense non-coding RNAs function to direct epigenetic complexes that regulate transcription in human cells. Epigenetics 2009; 4:296-301.
63. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D, Bièche I. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 2007; 67:3963-9.
64. Schrump DS. Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 2009; 15:3947-57.
65. Quintás-Cardama A, Santos FP, Garcia-Manero G, Medscape. Therapy with azanucleosides for myelodysplastic syndromes. Nat Rev Clin Oncol 2010; 7:433-44.
66. Brueckner B, Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 2004; 25:551-4.
67. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell 1980; 20:85-93.
68. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2V-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103:1635-40.
69. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23:3948-56.
70. Abujamra AL, Dos Santos MP, Roesler R, Schwartsmann G, Brunetto AL. Histone deacetylase inhibitors: a new perspective for the treatment of leukemia. Leuk Res 2010; 34:687-95.
71. cip1/waf1. Int J Biochem Cell Biol 2007; 39:1367-74.
72. INK4B demethylation and reexpression. Exp Hematol 2007; 35:263-73.
73. Greiner D, Bonaldi T, Eskeland R, Roemer E, Imhof A. Identification of a specific inhibitor of the histone methyltransferase SU(VAR)3-9. Nat Chem Biol 2005; 1:143-5.
74. Kubicek S, O'Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell 2007; 25:473-81.
75. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009; 8:1579-88.
76. Chen Z, Place RF, Jia ZJ, Pookot D, Dahiya R, Li LC. Antitumor effect of dsRNAinduced p21(WAF1/ CIP1) gene activation in human bladder cancer cells. Mol Cancer Ther 2008; 7:698-703.
77. Pfeifer GP, Steigerwald SD, Hansen RS, Gartler SM, Riggs AD. Polymerase chain reaction-aided genomic sequencing of an X chromosome-linked CpG island: methylation patterns suggest clonal inheritance, CpG site autonomy and an explanation of activity state stability. P Natl Acad Sci USA 1990; 87:8252-6.
78. McGarvey KM, Fahrner JA, Greene E, Martens J, Jenuwein T, Baylin SB. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res 2006; 66:3541-9.
79. Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001; 414:277-83.
80. Johnson L, Cao X, Jacobsen S. Interplay between two epigenetic marks. DNA methylation and histone H3 lysine 9 methylation. Curr Biol 2002; 12:1360-7.
81. Jackson JP, Lindroth AM, Cao X, Jacobsen SE. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 2002; 416:556-60.
82. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-9.
83. Mutskov V, Felsenfeld G. Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9. EMBO J 2004; 23:138-49.
84. Egger G, Aparicio AM, Escobar SG, Jones PA. Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment. Cancer Res 2007; 67:346-53.
85. Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, et al. DACT3 is an epigenetic regulator of Wnt/ beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 2008; 13:529-41.
86. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40:741-50.
87. Gal-Yam EN, Egger G, Iniguez L, Holster H, Einarsson S, Zhang X, et al. Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. P Natl Acad Sci USA 2008; 105:12979-84.
88. Sun F, Chan E, Wu Z, Yang X, Marquez VE, Yu Q. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells. Mol Cancer Ther 2009; 8:3191-202.
89. Rodriguez C, Borgel J, Court F, Cathala G, Forné T, Piette J. CTCF is a DNA methylation-sensitive positive regulator of the INK/ARF locus. Biochem Biophys Res Commun 2010; 392:129-34.